Sleep disorders are common non-motor symptoms in patients with Parkinson's disease. Our study aims to explore the relationship between non-apnea sleep disorders and future Parkinson's disease. This is a cohort study using a nationwide database. The participants were recruited from the Taiwan National Health Insurance Research Database between 2000 and 2003. A total of 91 273 adult patients who had nonapnea sleep disorders without pre-existing Parkinson's disease were enrolled. An age-, gender-, income-, urbanization-and Charlson comorbidity index score-matched control cohort consisting of 91 273 participants was selected for comparison. The two cohorts were followed for the occurrence of Parkinson's disease, death or until the end of 2010, whichever came first. The Kaplan-Meier analyses revealed patients with non-apnea sleep disorders tended to develop Parkinson's disease (logrank test, P < 0.001). After a multivariate adjustment in a Cox regression model, non-apnea sleep disorders was an independent risk factor for the development of Parkinson's disease [crude hazard ratio: 1.63, 95% confidence interval (CI): 1.54-1.73, P < 0.001; adjusted hazard ratio: 1.18, 95% CI: 1.11-1.26, P < 0.001]. In the subgroup analysis, patients with chronic insomnia (lasting more than 3 months) had the greatest risk (crude hazard ratio: 2.91, 95% CI: 2.59-3.26, P < 0.001; adjusted hazard ratio: 1.37, 95% CI: 1.21-1.55, P < 0.001). In conclusion, this study revealed that non-apnea sleep disorders, especially chronic insomnia, are associated with a higher risk for future Parkinson's disease.
Sleep disorders are common non-motor symptoms in patients with
Parkinson's disease. Our study aims to explore the relationship between non-apnea sleep disorders and future Parkinson's disease. This is a cohort study using a nationwide database. The participants were recruited from the Taiwan National Health Insurance Research Database between 2000 and 2003. A total of 91 273 adult patients who had nonapnea sleep disorders without pre-existing Parkinson's disease were enrolled. An age-, gender-, income-, urbanization-and Charlson comorbidity index score-matched control cohort consisting of 91 273 participants was selected for comparison. The two cohorts were followed for the occurrence of Parkinson's disease, death or until the end of 2010, whichever came first. The Kaplan-Meier analyses revealed patients with non-apnea sleep disorders tended to develop Parkinson's disease (logrank test, P < 0.001). After a multivariate adjustment in a Cox regression model, non-apnea sleep disorders was an independent risk factor for the development of Parkinson's disease [crude hazard ratio: 1.63, 95% confidence interval (CI): 1.54-1.73, P < 0.001; adjusted hazard ratio: 1.18, 95% CI: 1.11-1.26, P < 0.001]. In the subgroup analysis, patients with chronic insomnia (lasting more than 3 months) had the greatest risk (crude hazard ratio: 2.91, 95% CI: 2.59-3.26, P < 0.001; adjusted hazard ratio: 1.37, 95% CI: 1.21-1.55, P < 0.001). In conclusion, this study revealed that non-apnea sleep disorders, especially chronic insomnia, are associated with a higher risk for future Parkinson's disease.
IN TROD UCTI ON
Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease (Pringsheim et al., 2014) . Although the diagnosis of PD is based on the identification of motor symptoms, a variety of non-motor symptoms, such as olfactory deficits, constipation, urinary dysfunction, sleep disturbances, rapid eye movement sleep behaviour disorder (RBD) and depression, also constitute a substantial burden on the quality of life of patients (Friedman and Chou, 2004; Hawkes et al., 2010; Lin et al., 2014; Shen et al., 2013) .
Studies evaluating the relationship between sleep disorders and PD are largely cross-sectional, revealing that sleep ª 2017 European Sleep Research Society disturbance is prevalent in these patients (Friedman and Chou, 2004) . Epidemiological evidence addressing the influence of sleep disorders on the susceptibility of PD is limited to RBD (Hickey et al., 2007) and sleep apnea Sheu et al., 2015) . In contrast, other sleep disorders, such as insomnia, which is the most common sleep disorder, were not studied thoroughly. We hypothesized that sleep disorders other than sleep apnea [non-apnea sleep disorders (NSD)] would predispose patients to developing PD. We thus conducted a cohort study to explore this relationship by utilizing a nationwide database.
MATERI AL AND METHODS

Data source
The Taiwan National Health Insurance (NHI) programme is a government-launched, single-payer, mandatory insurance system and has been implemented since 1995, providing comprehensive health care for 99.9% of the Taiwanese population in 2014 (National Health Insurance Administration, 2014). The entire insurance claims database, namely the National Health Insurance Research Database (NHIRD), is managed and maintained by the National Health Research Institutes (NHRI) in Miaoli (Taiwan) (http://nhird.nhri.org.tw/ en/). The data sets used in this study were retrieved from the Longitudinal Health Insurance Database 2000 (LHID 2000) , which consisted of registration files and medical claims of approximately 1 000 000 randomly sampled beneficiaries collected from 1995 to 2010. The claims data include demographic data, diagnoses by the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) (Deyo et al., 1992) . To protect the individual's privacy, a consistent encryption procedure was applied to each patient's original identification. Nonetheless, linking the claims belonging to the same patient is feasible within the NHIRD data sets. The database is one of the largest population-based databases in the world and has been validated by the NHRI (http://nhird.nhri.org.tw/date_01.htm) as being representative of the entire Taiwanese population.
The current study was exempt from full review by the Institutional Review Board of Taipei Veterans General Hospital, because the study dealt with de-identified secondary data.
Study sample
To evaluate the association between the incidence of NSD and PD, a nationwide study with two cohorts, including the NSD cohort and the matched control cohort, were enrolled ( Fig. 1) . The NSD cohort included all adult patients (age ≥ 20 years) who were newly diagnosed with NSD [ICD-9 CM codes: 780.5 (sleep disturbances) and the 307.4 (specific disorders of sleep of nonorganic origin)] in the inpatient and outpatient claims data of LHID from January 2000 to December 2003. The control cohort was selected from the remaining participants in the LHID and was matched for age (AE5 years), gender, income, urbanization and Charlson comorbidity index (CCI) scores, which represent the burden of comorbidities at baseline (Charlson et al., 1987) . For both cohorts, if the subjects had a past medical history of sleep apnea [ICD-9 CM codes: 780.51 (insomnia with sleep apnea, unspecified), 780.53 (hypersomnia with sleep apnea, unspecified) and 780.57 (unspecified sleep apnea)] and PD (A code: A221 and ICD-9-CM code: 332) before enrolment, they were excluded from the study. The date of enrolment was defined as the date on which the sleep disorders were diagnosed initially. The participants with a follow-up period of fewer than 30 days were also excluded from the study.
Outcome
The primary outcome of the study was the occurrence of PD (ICD-9-CM code: 332). Both cohorts were followed from the date of enrolment until the occurrence of PD until the participants died, or until the end of the study (31 December 2010), whichever came first.
Statistical analysis
Data linkage, sampling and processing were assessed using Microsoft SQL Server 2008 R2 (Microsoft Corp., Redmond, WA, USA). Independent t-tests were used for parametric continuous variables, whereas Pearson's chisquare tests were utilized for comparisons between categorical variables. The incidences were compared based on the assumption of Poisson distribution with a 95% confidence interval (CI). Kaplan-Meier analyses and log-rank tests were used to compare the cumulative incidence of PD. For multivariate adjustments, including baseline comorbid diseases and the CCI scores, a Cox regression model was employed. To relieve the concern of surveillance bias, a sensitivity test was conducted after excluding subjected with PD diagnosis in the first year of follow-up. All statistical analyses were conducted using STATA statistical software (version 12.0; StataCorp, College Station, TX, USA). A twosided P-value of less than 0.05 was considered statistically significant.
RESULTS
Comparison of the baseline characteristics in the NSD and control cohorts
The demographic characteristics for all sampled participants are shown in Table 1 (Hsiao et al., 2015) . The controls were matched for age, gender, income, urbanization level and the CCI score (all P > 0.9). The mean age was 48.3 years [standard deviation (SD): 16.5 years], and the majority of participants in the two cohorts were female (61.6%). The follow-up period averaged 9.91 years. Patients with NSD had more comorbid diseases, including hypertension, coronary artery disease, cerebrovascular disease, dyslipidaemia, depressive disorder, non-steroidal anti-inflammatory drug (NSAID) use and more hypnotic use than controls (Table 1) .
A higher incidence of incident PD among NSD patients
There were 2978 new PD cases among the NSD cohort and 1833 among the matched-control cohort during the follow-up of 1 809 146 person-years (Table 2 ). The average duration from the enrolment date to the date of PD diagnoses was 5.4 AE 3.3 years. For NSD patients, the crude and adjusted hazard ratios (HRs) for all PD cases were 1.63 [95% confidence interval (CI): 1.54-1.73; P < 0.001] and 1.18 (95% CI: 1.11-1.26; P < 0.001), respectively ( Table 2 ). The Kaplan-Meier analyses also revealed that NSD patients had a higher risk for future PD (log-rank test, P < 0.001, Fig. 2 ). If subjects with PD diagnoses in the first year of follow-up were excluded, the adjusted HR of NSD on PD development is 1.16 (95% CI: 1.08-1.24; P < 0.001), which remains significant. In the subgroup analysis, the relationship between the different types of NSD and PD was also examined. The adjusted HRs (95% CI) were 1.21 (1.12-1.31) for acute insomnia; 1.37 (1.21-1.55) for chronic insomnia; 1.12 (1.03-1.21) for sleep disturbance; and 1.18 (1.03-1.35) for other NSD (Table 2) .
DISCUSSION
To our knowledge, this study is the largest study probing the relationship between sleep disorders and Parkinson's disease. Our results reveal that NSD is an independent risk factor for the development of future PD (crude HR: 1.63, 95% CI: 1.54-1.73, P < 0.001; adjusted HR: 1.18, 95% CI: 1.11-1.26, P < 0.001). Among the sleep disorders that were investigated, chronic insomnia confers the highest risk to PD (crude HR: 2.91, 95% CI: 2.59-3.26, P < 0.001; adjusted HR: 1.37, 95% CI: 1.21-1.55, P < 0.001), followed by acute insomnia (crude HR: 1.79, 95% CI: 1.66-1.92, P < 0.001; adjusted HR: 1.21, 95% CI: 1.12-1.31, P < 0.001).
PD is a multi-system neurodegenerative disorder characterized by a loss of dopaminergic neurones in the substantia nigra and the aggregation of the misfolded protein a-synuclein, also known as Lewy pathology, throughout the central, autonomic and peripheral nerve systems (Chaudhuri and Schapira, 2009; Del Tredici and Braak, 2012) . The former is responsible for the core motor features of PD. The latter is correlated to multiple non-motor symptoms, which often precedes the motor diagnosis of PD for decades (Chaudhuri and Schapira, 2009 ). Accumulation of a-synuclein in the caudal raphe nuclei and the coeruleus-subcoeruleus complex in the pons may result in the dysregulation of sleep and wakefulness cycles and forms the basis of disordered sleep habits, such as excessive daytime sleepiness (EDS) and RBD (Hawkes et al., 2010) . Supplementation with levodopa not only provides improvement of motor symptoms but also improves sleep quality in PD patients, further supporting the link between PD and sleep disturbance (Leeman et al., 1987; Rye and Jankovic, 2002) . 307.41, 307.42; sleep disturbance: 780.5, 780.50; others: 780.55, 780.56, 780.59, 307. Sleep disturbance is prevalent in patients with PD (Friedman and Chou, 2004) . Insomnia, the most common sleep disorder, affects more than 50% of PD patients (Gjerstad et al., 2006 (Gjerstad et al., , 2007 , and the prevalence increases progressively with the duration of the disease (Maass and Reichmann, 2013; Zoccolella et al., 2011) . In addition to primary insomnia, the associated symptoms in PD, such as nocturnal akinesia or nocturia, may also impair the integrity of sleep of such patients (Dhawan et al., 2006; Lees et al., 1988) . In contrast, research investigating the impact of sleep disorders on the susceptibility of PD is limited. We conducted our cohort study for this reason. Our results further support a bidirectional relationship between PD and sleep disorders. Particularly, some comorbidities manifesting with sleep disorders, such as depression, were associated probably with future PD development (Shen et al., 2013) and were adjusted in the current study.
Longitudinal studies evaluating the future development of PD among patients with sleep disorders were limited. One review paper analysed 17 cohort studies, but more than half of them were small in size, enrolling less than 100 study subjects. Besides, these studies focused mainly on patients with RBD, and revealed that 9-65% RBD patients developed PD during a follow-up period of 1.8-11.1 years (Zoccolella et al., 2011) . Several other studies probed into the relationship of sleep schedule/duration and Parkinsonism. One prospective research study investigated female nurses who worked night shifts, and found that longer sleeping hours in a 24-h period led to a higher incidence of PD in comparison to those who slept for fewer hours (Chen et al., 2006) . Another study found that longer daytime napping was associated with the future occurrence of PD. In the analysis for night-time sleeping, both shorter (<5 h) and longer (>9 h) sleeping durations were associated with an increased risk of PD (Gao et al., 2011) . Further research is required to clarify the relation between sleep and PD.
Because NHI is a single-payer, mandatory insurance programme, a matched control cohort design allows us to trace the majority of events with minimal referral bias, which is the main strength of our study. Moreover, the study power is significant due to the large sample size of study participants. Nevertheless, there are some limitations to our study. First, diagnoses of PD and sleep disorders could be less accurate compared to diagnoses made by standardized criteria because of the use of administrative claims data, which may be an inherent weakness for all database research. Secondly, some personal information, including accurate severity and potential risk factors of PD, such as family history, exposure of toxin (e.g. trichloroethylene, copper, manganese or lead), smoking status and body mass index, could not be obtained from our database. Furthermore, our study did not enter into detail concerning nocturnal polysomnographic studies (if any), sleep depth, sleep duration or the extent of sleep disruption, which may need further prospective research to clarify their influence on the development of PD.
CONC LUSION
Patients with NSD had a higher risk of developing PD. Further investigation is required to confirm our results and to elucidate the mechanism underlying the association.
